Related Experiment Video
Updated: Jul 15, 2026

11:27
Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging
Published on: December 4, 2016
Molecular interactions between dimethoxycurcumin and Pamam dendrimer carriers
Eleni Markatou1, Vassilis Gionis, Georgios D Chryssikos
1School of Pharmacy Department of Pharmaceutical Technology, Panepistimiopolis Zografou 15771, University of Athens, Athens, Greece.
International Journal of Pharmaceutics
|April 13, 2007
Summary
Dimethoxycurcumin, a curcumin analog from turmeric, shows anticancer potential but poor solubility. Conjugating it to water-soluble PAMAM dendrimers enhances its delivery for potential cancer therapy.
Area of Science:
- Medicinal Chemistry
- Nanotechnology
- Pharmacology
Background:
- Dimethoxycurcumin, derived from turmeric (Curcuma longa), exhibits potent anticancer activity against various cell lines.
- Poor water solubility limits the therapeutic application of dimethoxycurcumin as an anticancer agent.
Purpose of the Study:
- To conjugate dimethoxycurcumin with water-soluble Poly(amidoamine) (PAMAM) dendrimers.
- To enhance the solubility and delivery of dimethoxycurcumin for potential cancer treatment.
Main Methods:
- Conjugation of dimethoxycurcumin to PAMAM dendrimers of generations 3.5 (G3.5) and 4 (G4).
- Fourier Transform Infrared Attenuated Total Reflectance (FTIR-ATR) spectroscopy to analyze drug-dendrimer interactions.
Main Results:
- Successful conjugation of dimethoxycurcumin to G3.5 and G4 PAMAM dendrimers.
- Maximum drug-dendrimer incorporation efficiencies of 4.3 molar (G3.5) and 5.0 molar (G4).
- FTIR-ATR analysis confirmed dimethoxycurcumin's enolic form and revealed conformational changes in dendrimer amine groups upon interaction.
Conclusions:
- PAMAM dendrimers effectively enhance the water solubility of dimethoxycurcumin.
- The drug-dendrimer conjugation strategy holds promise for developing improved dimethoxycurcumin-based cancer therapies.

